

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

**Claim 1. (previously presented)** A therapeutic agent for glaucoma comprising a combination of pharmaceutically effective amounts of (i) a Rho kinase inhibitor and (ii) a  $\beta$ -blocker, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide.

**Claim 2. (previously presented)** A therapeutic agent for glaucoma which comprises a combination of pharmaceutically effective amounts of (i) a Rho kinase inhibitor and (ii) a  $\beta$ -blocker, and they complement and/or enhance their actions with respect to each other, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide.

**Claim 3. (canceled)**

**Claim 4. (original)** The therapeutic agent for glaucoma as claimed in claim 1 or 2, wherein the  $\beta$ -blocker is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.

**Claim 5. (withdrawn)** A method of treating glaucoma comprising administering effective amounts of a Rho kinase inhibitor in combination with a  $\beta$ -blocker to a patient.

**Claim 6. (withdrawn)** A method of treating glaucoma comprising administering effective amounts of a Rho kinase inhibitor in combination with a  $\beta$ -blocker to a patient, thereby they complement and/or enhance their actions with respect to each other.

**Claim 7. (withdrawn)** The method of treating glaucoma as claimed in claim 5 or 6, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

**Claim 8. (withdrawn)** The method of treating glaucoma as claimed in claim 5 or 6, wherein the  $\beta$ -blocker is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.

**Claim 9. (withdrawn)** Use of a combination of a Rho kinase inhibitor and a  $\beta$ -blocker in the manufacture of a therapeutic agent for glaucoma.

**Claim 10. (withdrawn)** Use of a combination of a Rho kinase inhibitor and a  $\beta$ -blocker in the manufacture of a therapeutic

agent for glaucoma, characterized in that their actions are complemented and/or enhanced each other.

**Claim 11. (withdrawn)** The use of the combination of the Rho kinase inhibitor and the  $\beta$ -blocker as claimed in claim 9 or 10, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexane-carboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

**Claim 12. (withdrawn)** The use of the combination of the Rho kinase inhibitor and the  $\beta$ -blocker as claimed in claim 9 or 10, wherein the  $\beta$ -blocker is timolol, befunolol, carteolol, niplradilol, betaxolol, levobunolol or metipranolol.

**Claim 13. (new)** The therapeutic agent for glaucoma as claimed in claim 1 or 2, wherein the  $\beta$ -blocker is timolol.